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ABSTRACT
Background
This economic analysis aimed to determine, from 
the perspective of a Canadian provincial government 
payer, the cost-effectiveness of docetaxel (Taxotere: 
Sanofi–Aventis, Laval, QC) in combination with dox-
orubicin and cyclophosphamide (t a c ) compared with 
5-fluorouracil, doxorubicin, and cyclophosphamide 
(f a c ) following primary surgery for breast cancer in 
women with operable, axillary lymph node–positive 
breast cancer.
Methods
A Markov model looking at two time phases—5-year 
treatment and long-term follow-up—was constructed. 
Clinical events included clinical response (based 
on disease-free survival and overall survival) and 
rates of febrile neutropenia, stomatitis, diarrhea, 
and infections. Health states were “no recurrence,” 
“locoregional recurrence,” “distant recurrence,” and 
“death.” Costs were based on published sources and 
are presented in 2006 Canadian dollars. Model inputs 
included chemotherapy drug acquisition costs, che-
motherapy administration costs, relapse and follow-
up costs, costs for management of adverse events, 
and costs for granulocyte colony-stimulating factor 
(g-c s f ) prophylaxis. A 5% discount rate was applied 
to costs and outcomes alike. Health utilities were 
obtained from published sources.
Results
For t a c  as compared with f a c , the incremental cost 
was $6921 per life-year (l y ) gained and $6,848 per 
quality-adjusted life-year (q a l y ) gained. The model 
was robust to changes in input variables (for example, 
febrile neutropenia rate, utility). When g-c s f  and 
antibiotics were given prophylactically before every 
cycle, the incremental ratios increased to $13,183 and 
$13,044 respectively.
Conclusions
Compared with f a c , t a c  offered improved response 
at a higher cost. The cost-effectiveness ratios were 
low, indicating good economic value in the adjuvant 
setting of node-positive breast cancer patients.
KEY WORDS
Adjuvant chemotherapy, breast cancer, cost analysis, 
economic model, prophylaxis
1.  INTRODUCTION
The multicentre phase iii randomized Breast Cancer 
International Research Group (b c i r g) 001 trial (“t a c –
f a c ”) showed that efficacy with docetaxel (Taxotere: 
Sanofi–Aventis, Laval, QC) in combination with 
doxorubicin and cyclophosphamide (t a c  protocol) 
was improved over that with the standard protocol 
of 5-fluorouracil, doxorubicin, cyclophosphamide 
(f a c ) for the adjuvant treatment of patients with oper-
able node-positive breast cancer. The study observed 
1491 women between the ages of 18 and 70 years 
with axillary node–positive breast cancer who were 
randomly assigned to 6 cycles of either t a c  or f a c  as 
adjuvant chemotherapy after surgery. Administration 
of granulocyte colony–stimulating factor (g-c s f) was 
given to only patients who experienced 1 episode of 
febrile neutropenia or infection.
As compared with f a c , the t a c  regimen was 
associated with a higher incidence of febrile neutro-
penia, but this higher incidence did not result in a 
significantly different or elevated rate of moderate-
to-severe infection in the patients who received t a c  
chemotherapy. During a 5-year follow-up period, the 
study showed improved disease-free survival (d f s , 
primary efficacy endpoint) and overall survival (o s , 
secondary endpoint) for patients receiving the t a c  
protocol as compared with those receiving the f a c  
protocol 1. The expansion of the indication for t a c  
from advanced to early breast cancer may lead to an 
increase in chemotherapy expenditures for hospitals 
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and provincial payers alike. However, recurrences 
avoided by the use of t a c  will have an effect in terms 
of years of life saved and may generate cost savings 
attributable to the reduction in disease recurrence.
2.  OBJECTIVE
The objective of the present economic analysis was to 
compare, from the perspective of Cancer Care Ontario 
(c c o ) and the Ontario Ministry of Health and Long-
Term Care, the effectiveness, cost, and incremental 
cost-effectiveness of two adjuvant chemotherapy 
strategies after primary surgery for breast cancer in 
women with operable, axillary lymph node–positive 
breast cancer:
●  t a c   Docetaxel 75 mg/m2 as a 1-hour intravenous 
(IV) infusion, in combination with doxorubicin 
50 mg/m2 as an IV infusion and cyclophosph-
amide 500 mg/m2 as an IV infusion, all given on 
day 1 every 3 weeks for 6 cycles.
●  f a c   5-Fluorouracil 500 mg/m2 as an IV infusion, 
in combination with doxorubicin 50 mg/m2 as an 
IV infusion and cyclophosphamide 500 mg/m2 as 
an IV infusion, all given on day 1 every 3 weeks 
for 6 cycles.
3.  METHODS
The t a c –f a c  study showed that 6 cycles of the t a c  
protocol were superior to 6 cycles of the f a c  protocol 
with respect to d f s  and o s  in a group of patients with 
node-positive breast cancer over a 5-year time hori-
zon 1. The cost of t a c  is greater than the cost of f a c  
when it comes to acquisition, administration, and ad-
verse event management. Given the superior efficacy 
but higher cost of t a c , a cost-effectiveness analysis 
was considered a reasonable economic evaluation 2. 
An incremental cost per life-year (l y ) gained was the 
primary economic outcome. A secondary economic 
outcome was the incremental cost per quality-adjusted 
life-year (q a l y ) gained.
A Markov model (Figure 1), developed from the 
perspective of c c o  and the Ontario Ministry of Health 
and Long-Term Care, was used to follow a population 
of patients treated in the t a c –f a c  study [1480 subjects, 
99.3% of the overall population; 744 in the t a c  arm 
(99.9%), 736 in the f a c  arm (98.7%); median age: 
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f i g u r e  1  The model as a decision tree. pDeath... = probability of death from the indicated state [No Relapse, Loc (locoregional) Relapse, 
distant Met (metastatic) Relapse]; pRelapse = probability of relapse from the No Relapse state; pMetRelapse = probability of distant Met 
relapse from the Loc Relapse state; PercentMetRelapse = proportion of distant Met Relapse.9
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49.0 years]. Patients in the t a c  arm experienced 141 
recurrences (19.0%) and 162 deaths (21.8%); in the f a c  
arm, the numbers were 195 (26.5%) and 246 (33.4%) 
respectively 3,4. A cycle length of 6 months was used. 
The decision–analytic model started at the initiation of 
adjuvant chemotherapy. The model measured disease 
recurrences within the remaining years of life for all 
patients, and it comprises these health states:
●  No Recurrence:  No disease progression
●  Locoregional Recurrence:  Recurrence without 
metastases
●  Distant (Metastatic) Recurrence:  Recurrence 
with metastases
●  Deceased:  Patient died (from breast cancer cause 
or other causes)
“Deceased” is an “absorbing state.” Any given woman 
could stay in the other three “non-absorbing” health 
states for more than one Markov cycle.
All women start in the No Recurrence state. 
Any given women could stay at the same state for 
more than one cycle or progress into the next state, 
with the final state being Deceased (Figure 1). The 
lifetime horizon included two time periods, a period 
of treatment and observation (5 years, correspond-
ing to the length of the t a c –f a c  study) and a period 
of follow-up for surviving patients (beyond the 5th 
year until death).
The construct of this model makes certain as-
sumptions. Recurrences (at 5 years) are considered 
mutually exclusive: patients could have either a Lo-
coregional or Distant (Metastatic) recurrence. Death 
can occur after the No Recurrence, Locoregional 
Recurrence, or Distant (Metastatic) Recurrence states. 
In the base-case analysis, the assumption was made 
that filgrastim (g-c s f ) was given secondary to an 
episode of febrile neutropenia per the t a c –f a c  study 
protocol, and a standard weight was used for patients. 
Transfusion rates were based on the percentage of 
patients that had a “need for blood transfusions” as 
reported in the t a c –f a c  study 1. The base-case analysis 
comparing t a c  with f a c  was constructed using the 
entire population of the t a c –f a c  study and g-c s f  as 
secondary prophylaxis for febrile neutropenia over a 
lifetime time horizon.
Two measures of effectiveness (outcome) were 
considered in the analysis: l y s gained (based on study 
d f s ) and q a l y s gained. Grade 3 or 4 serious adverse 
events of febrile neutropenia, stomatitis, diarrhea, 
and infection 1 were included. Results at 5 years from 
the t a c –f a c  study were used to derive the 6-month 
constant probabilities of Locoregional Recurrence 
and Distant (Metastatic) Recurrence, and the 6-month 
constant probabilities of Death for patients coming 
from any previous state [No Recurrence, Locoregional 
Recurrence, and Distant (Metastatic) Recurrence].
Health utilities were not collected during the 
t a c –f a c  study, and we therefore obtained sources in 
the literature 5–7. The disutility associated with the 
use of docetaxel in the t a c  arm was based on the 
disutility associated with adverse events in patients 
who had received docetaxel in the t a c –f a c  study, 
the probability of an adverse event, the number of 
adverse events, and the duration of adverse events in 
that study 1,3. The disutility associated with adverse 
events was calculated to be 0.0072 for the t a c  regi-
men and was found to be 0.0035 8 for the f a c  regi-
men, for a difference of 0.0037. In the base case, the 
utility value for the f a c  regimen was assumed to 0.72 
(reflecting utility values for adjuvant chemotherapy 9 ) 
and the utility value for the t a c  regimen was calculated 
to 0.7163 (based on the utility value for f a c , less the 
incremental disutilities attributable to the adverse 
events: 0.72 – 0.0037). Utility values for health states 
were the same for both groups. For No Recurrence, 
Locoregional Recurrence, and Distant (Metastatic) 
Recurrence, utility values were 0.960 5, 0.816 5, and 
0.49–0.65 6 (mean: 0.57) 7 respectively.
3.1  Costs
Model costs included direct medical costs—namely, 
drug acquisition costs for the t a c  and f a c  treatments; 
adverse events costs for grades 3 and 4 febrile neutro-
penia, stomatitis, diarrhea, and infection; and costs of 
primary and secondary prophylaxis with g-c s f . Infu-
sion times for drug administration were considered in 
the calculation of drug costs. Costs associated with 
chemotherapy administration, with follow-up, and 
with Distant (Metastatic) and Locoregional recur-
rence chemotherapy regimens, supportive care, and 
diagnostic tests were also considered.
Costs of the assessed treatments included drug 
acquisition and administration costs, which include 
2.5 hours of chair time for t a c  and 1.5 hours of chair 
time for f a c , with nursing and overhead, for the 6 
cycles of treatment. These costs were applied once 
in the model at the starting point (time 0). Drug ac-
quisition costs were obtained from c c o  and Sanofi–
Aventis Canada.
The model uses 2006 Canadian costs. All non–
2006 costs were inflated to 2006 Canadian dollars. 
Costs and outcomes were discounted at a rate of 5% 2. 
Nonmedical and indirect costs were not considered 
in the analysis, per the provincial ministry of health 
perspective. The cost of capital equipment was not 
included in this analysis. The equipment to admin-
ister t a c  was assumed to exist in a hospital setting 
established to administer chemotherapy.
3.1.1  Costs of Chemotherapies for Subsequent  
Metastatic Disease
After the administration of adjuvant chemotherapy, 
the costs of subsequent chemotherapy for patients 
in the metastatic setting were based on advanced 
breast cancer treatment protocols from the c c o  Drug 
Formulary 10. The cost of a treatment comprises drug 10
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acquisition costs and chemotherapy administration 
time. The protocol was multiplied by its percent 
utilization, and protocols were then stratified into 
first-line, second-line, and third-line chemotherapy 
regimens based on c c o  practice guidelines 10. It 
was assumed that the costs for fourth- and fifth-line 
chemotherapy would be the same as for third-line 
chemotherapy. Table i details the specific regimens 
given as subsequent lines of therapy in the f a c  and t a c  
groups. In the t a c  arm, in the first line, trastuzumab 
and vinorelbine were given to patients positive for 
the human epidermal growth factor receptor (h e r 2+), 
and capecitabine or vinorelbine were given to patients 
negative for the receptor (h e r 2–). In the f a c  arm, in 
the first line, trastuzumab and docetaxel were given 
to h e r 2+ patients, and docetaxel was given to h e r 2– 
patients. In the second line, h e r 2+ and h e r 2– patients 
in both arms were given capecitabine. In the t a c  arm, 
h e r 2– patients could receive vinorelbine instead of 
capecitabine. In the third line, docetaxel was given 
to h e r 2+ patients in the t a c  arm, and vinorelbine was 
given to h e r 2+ patients in the f a c  arm.
3.1.2  Costs of Supportive Care
In the model, supportive care costs consisted only of 
concomitant medications used in the administration 
of chemotherapy (Table i). Costs for transfusions 
were determined by multiplying the proportion of 
patients described as having had a “need for a blood 
transfusion” per the t a c –f a c  study results by the cost 
of the transfusion. All patients received ondansetron 
for nausea and dexamethasone; the average cost of 
ondansetron and dexamethasone per patient was cal-
culated (Trudeau M. Personal communication). The 
final average supportive care cost per patient entered 
into the model was $65.08.
3.1.3  Costs of Adverse Events
With respect to adverse events, only grade 3 or 4 events 
with statistically significant differences between the 
two evaluated regimens and potentially leading to 
hospitalization were considered in the model. The 
adverse events considered were febrile neutropenia, 
stomatitis, diarrhea, and infection (Table ii). All 
other adverse events reported (for example, anemia, 
t a b l e  i  Cost of drug treatment, chemotherapy regimens, supportive care, adverse events, diagnostic procedures, and follow-up procedures, 
Canadian dollars
Variable t a C f a C Source
Cost of drug treatment
Drug acquisition
  (6 cycles)
9,024.00 301.92 Cancer Care Ontario, 2006 9
Chemotherapy administration
  (6 cycles)
1,522.08 913.26 Chair time: Cancer Care Ontario Drug Formulary
Nursing and overhead costs: 2002 costsa ($35/h and 
$57.42/h respectively) inflated to 2006 using the Bank 
of Canada inflation calculator 11
TOTAL 10,546.08 1,215.18 Drug acquisition plus chemotherapy administration
Chemotherapy regimens
First-line 10,686–54,264b 11,700–47,892c
Cancer Care Ontario, 2006 9 (range for h e r 2– to h e r 2+)
Second-line 3,300–10,686d 3,300e
Third-line 18,072f 11,700g Cancer Care Ontario, 2006 9 (h e r 2+)
Supportive care cost components
Transfusion 41.60 13.56
Sunnybrook Health Sciences Centre, 2005 12 Ondansetron 31.50 31.50
Dexamethasone 6.00 6.00
TOTAL 79.10 51.06 Derived from the foregoing category costs and the  
proportion of patients receiving the therapies
Average supportive care cost
  used in the model
65.08 65.08 Average supportive care cost for the t a c  and f a c  arms
Cost of adverse events
Febrile neutropenia 2,367.23 2,367.23
Ontario Case Cost Initiative, 2005 13
Bank of Canada inflation calculator 11
Stomatitis 3,151.18 3,151.18
Diarrheas 2,760.30 2,760.30
Infections 2,367.30 2,367.30
g-c s f  acquisition cost
  for secondary prevention
  of febrile neutropenia
1,239.77 1,239.77 Sunnybrook Health Sciences Centre, 2005 12
Lalami et al., 2004 14
}
}
}
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Variable t a C f a C Source
Cost of diagnostic procedures performed at diagnosis
TOTAL 643.04 643.04 Procedures from Will et al., 2000 15
Ontario Ministry of Health and Long-Term Care, 2004 16  
(validated by the clinical authors of this manuscript)
Total cost of laboratory tests
Total cost of all blood work 41.95 41.95 Ontario Ministry of Health and Long-Term Care, 2004 16
Follow-up costsh
Total average annual
    follow-up cost for years 1–3 for 
patients without breast cancer 
recurrence
582.82 582.82 Will et al., 2000 15 ($467 non-inflated)
Bank of Canada inflation calculator 11 (inflated to $582.82)
Total average annual
    follow-up cost for years beyond 
year 3 for patients without breast 
cancer recurrence
356.93 356.93 Will et al., 2000 15 ($286 non-inflated)
Bank of Canada inflation calculator 11 (inflated to $356.93)
Total average annual 
    follow-up cost for patients with 
distant (metastatic) breast cancer
1,729.10 1,729.10 Costs and codes from Ontario Ministry of Health and 
Long-Term Care, 2004 16 (procedure validated by the 
clinical authors of this manuscript)
Total average annual
    follow-up cost for patients 
with locoregional breast cancer 
recurrence
805.89 805.89 Will et al., 2000 15 ($827 for years 1 and 2, $612 for 
years 3 and 4, $497 for years 5 and 6)
Bank of Canada inflation calculator 11 (inflated to $1,032.76 
for years 1 and 2, to $764.27 for years 3 and 4, to $620.65 
for years 5 and 6)
Annual cost based on an average of 6 years
a  Risebrough NA, Imrie K, Seung SJ, et al. An observational study of resource use and outcomes in indolent follicular non-Hodgkin’s 
lymphoma for Canada. Unpublished data. 2002.
b  h e r 2–: capecitabine or vinorelbine; h e r 2+: trastuzumab plus vinorelbine.
c  h e r 2–: docetaxel; h e r 2+: trastuzumab plus docetaxel.
d  h e r 2–: capecitabine or vinorelbine; h e r 2+: capecitabine.
e  h e r 2+: capecitabine.
f  h e r 2+: docetaxel.
g  h e r 2+: vinorelbine.
h  Follow-up care includes physician assessments, clinic costs (including overhead), hematology, biochemistry, bone scan, chest radiog-
raphy, liver ultrasonography, and annual mammogram 15.
t a c  = docetaxel, doxorubicin, cyclophosphamide; f a c  = 5-fluorouracil, doxorubicin, cyclophosphamide; h e r 2– = disease negative for the 
human epidermal growth factor receptor; h e r 2+ = disease positive for the human epidermal growth factor receptor.
t a b l e  i  (Continued)
t a b l e  ii  Percentage of grades 3 and 4 adverse events 1
Regimen Treated
population (n)
Adverse events (%)
Febrile neutropeniaa     Mucositis and stomatitisa Diarrheaa Infectionsa,b
  t a c 744 24.7     7.10 3.80 3.90
  f a c 736 2.50     2.00 1.80 2.20
a  Extracted from Martin et al., 2005, Table 3, p. 2310 1.
b  Non-hematologic infections.
t a c  = docetaxel, doxorubicin, cyclophosphamide; f a c  = 5-fluorouracil, doxorubicin, cyclophosphamide.
thrombocytopenia, asthenia, vomiting and nausea, 
abdominal pain, and so on) were assumed to have a 
marginal effect on the economic outcomes, because 
they were not statistically different between the two 
groups 1. The model assumed that the adverse events 
were considered to be directly associated with the 
t a c  and f a c  chemotherapies and to occur over the 
treatment period, per the results of the t a c –f a c  study. 
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Codes from the International Statistical Classifica-
tion of Diseases and Related Health Problems, 10th 
revision, for febrile neutropenia, stomatitis, diarrhea 
and infection were determined and costed using the 
Ontario Case Costing Initiative 13. These costs were 
applied once in the model at the starting point (time 0, 
corresponding to the advanced treatment phase). The 
cost of febrile neutropenia included hospitalization 
costs and treatment of febrile neutropenia with g-c s f . 
Per the t a c –f a c  study, all patients received prophy-
lactic antibiotics 1 at a cost of $314.10. An average 
adverse event cost per patient was calculated based 
on the percentage occurrence of each adverse event 
multiplied by the cost per event. Diagnostic and pro-
cedural costs associated with the treatment of breast 
cancer are listed in Table i.
3.1.4  Follow-Up Costs
Information on follow-up procedures and the frequen-
cy of those procedures was validated by the clinical 
authors of this article. Associated costs were obtained 
from the Ontario Ministry of Health and Long-Term 
Care Schedule of Benefits 16. Procedures included phy-
sician or oncologist visits, mammograms, laboratory 
testing, and radiology. Annual costs were determined 
by multiplying costs per episode by the annual fre-
quency of the procedure, and a total annual cost of 
all follow-up procedures was obtained.
For women with Distant (Metastatic) Recurrence, 
the total annual cost of follow-up was determined to 
be $1,729.10.
Follow-up costs for women without recurrence of 
breast cancer included physician assessments, clinical 
costs (including overhead), hematology, biochemis-
try, bone scan, chest radiographs, liver ultrasound, 
and annual mammogram 15. The cost was stated as 
$582.82 in year 1, declining to $356.93 by year 5, 
after inflation. It was assumed that years 1–3 had a 
follow-up cost of $582.82 and that all years thereafter 
had a cost of $356.93.
Follow-up costs for women with Locoregional 
Recurrence were $1,032.76 for years 1 and 2, $764.27 
for years 3 and 4, and $620.65 for years 5 and beyond, 
after inflation. The annual cost was $805.89, based 
on an average of 6 years (Table i).
3.1.5  Cost of Secondary Prophylaxis with G-CSF after a 
First Episode of Febrile Neutropenia
The average cost per patient for secondary prophy-
laxis with g-c s f  was determined by multiplying the 
cost per event by the proportion of patients who 
received any secondary prophylaxis by the average 
number of cycles for which they received secondary 
prophylaxis (Table iii). Detailed secondary prophy-
laxis information was not available from the publi-
cation. Here, the unpublished clinical study report 
was used to provide the data. The average cost per 
patient of secondary prophylaxis was considered 
only once for each arm of treatment at the starting 
point of the model (time 0, corresponding to the 
adjuvant treatment phase).
3.1.6  Cost of Primary Prophylaxis of Febrile Neutrope-
nia with G-CSF
In the t a c –f a c  study, patients who experienced 
febrile neutropenia received g-c s f  (secondary 
prophylaxis). We wanted to conduct an alterna-
tive analysis looking at the cost-effectiveness of 
t a c  versus f a c  in the context of primary g-c s f 
prophylaxis—that is, the administration of g-c s f  
before the occurrence of febrile neutropenia or 
other documented infection. To do so, we used the 
g e i c a m  (Grupo Español de Investigación del Cáncer 
de Mama) 9805 study 17 for the costing of adverse 
events, because we could then compare adverse 
events rates with and without primary prophylaxis 
within the context of a single study. Because the 
rate of febrile neutropenia in the t a c  group was the 
major driver of adverse event costs and the variable 
that would be affected by g-c s f  prophylaxis, it is 
important to note that the adverse event rates for 
grades 3 and 4 febrile neutropenia reported in the 
g e i c a m  study for the pre-t a c  and f a c  groups were 
similar to those reported in the t a c –f a c  study 1. 
In this scenario, as in our base-case analysis, all 
patients received antibiotic prophylaxis.
3.2  Sensitivity Analysis
Sensitivity analyses (one-way and bootstrapping) 
were conducted to test the robustness of results with 
regard to variations in key parameters considered in 
the model. Sensitivity analyses were conducted for 
adverse event rates, the rate of febrile neutropenia, 
the proportion of recurrences in the Locoregional 
and Distant (Metastatic) recurrence states, follow-
up and supportive care costs, utility values, and 
transition probabilities. Table iv outlines the spe-
cific analyses.
t a b l e  iii  Secondary granulocyte colony–stimulating factor (g-c s f ) 
prophylaxisa
t a C f a C
Treated population (n) 744 736
Patients receiving prophylaxis  
[n (%)]
217 (29.17) 41 (5.57)
Cycles with prophylaxis [n (%)] 799 (18.7) 126 (2.9)
Average cycles under prophylaxis 
(N/n)
3.7 (799/217) 3.1 (126/41)
Average prophylaxis administra-
tions per patient (N/n)
1.07 
(799/744)
0.17  
(126/736)
a  From Aventis Pharma Research and Development, 2004, 
Table 78, p. 193 3.
t a c  = docetaxel, doxorubicin, cyclophosphamide; f a c  = 5-fluor-
ouracil, doxorubicin, cyclophosphamide.
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t a b l e  iv  Incremental cost-effectiveness ratio (i c e r) and incremental 
cost–utility ratio (i c u r ) summary table, Canadian dollars
Variable and variations i C e r
(CA$)
i C u r
(CA$)
Base case 6,921.24 6,848.39
Adverse event rates (g e i c a m  study 19) 6,893.22 6,820.66
Adverse event rates
Rates increased by 25% 7,129.14 7,054.09
Rates decreased by 25% 6,713.35 6,642.68
Rates in t a c  increased by 25% 7,188.70 7,113.03
Rates in t a c  decreased by 25% 6,653.78 6,583.74
Rates of febrile neutropenia increased 
by 25%
7,076.75 7,002.26
Rates of febrile neutropenia in 
decreased by 25%
6,765.74 6,694.52
Relapse rate
Increased probability of relapse by 
25% in t a c  arm
21,126.10 21,126.10
Decreased probability of relapse by 
25% in t a c  arm
2,715.32 2,661.37
Follow-up cost
No recurrence + 25% metastatic – 25% 7,148.54 7,073.29
No recurrence – 25% metastatic + 25% 6,693.94 6,623.48
Ratio of recurrence
Recurrence at 25% 7,203.09 7,127.26
Recurrence at 100% 6,357.56 6,290.63
Utility
Equate utility value 6,921.24 6,777.05
Lowest utility value 6,921.24 7,393.15
Highest utility value 6,921.24 6,571.69
Bootstrapping
Best case 3,132.16 3,060.59
Worst case 20,370.59 20,036.64
Primary prophylaxis (g-c s f ) 13,183.26 13,044.49
Adverse event rates (g e i c a m  study rates 19)
Rates increased by 25% 13,277.28 13,137.52
Rates decreased by 25% 13,089.32 12,951.54
Rates in t a c  increased by 25% 13,355.05 13,214.47
Rates in t a c  decreased by 25% 13,011.47 12,874.51
Rates of febrile neutropenia increased 
by 25%
13,265.49 13,125.86
Rates of febrile neutropenia decreased 
by 25%
13,101.03 12,963.12
Relapse rate
Increased probability of relapse by 
25% in t a c  arm
37,736.72 37,736.72
Decreased probability of relapse by 
25% in t a c  arm
6,581.31 6,411.48
t a c  = docetaxel, doxorubicin, cyclophosphamide; g-c s f  = granu-
locyte colony–stimulating factor.
3.2.1  Analysis
An incremental cost-effectiveness analysis was 
conducted for the base-case analysis. A number of 
one-way and bootstrapping sensitivity analyses were 
conducted as described in the preceding subsection. 
Additionally, an alternative analysis using g-c s f  as 
primary prophylaxis was conducted, and sensitivity 
analyses were built around that model as well.
A number of assumptions were made in construct-
ing this model:
●  Transition probabilities were constant over time. 
Because recurrence rates were available only at 
5 years, 5-year rates were converted into 6-month 
probabilities such as the probability of any single 
patient having a recurrence in any given model cycle 
(semester). The formula for the time conversion is
1 – e–rate * time.
For instance, if 30% of women experienced a 
recurrence at 5 years (ten Markov cycles), the 
constant 6-month transition probability was
0.029 [1 – e–0.3 * 1 / 10]
●  Recurrences were considered mutually exclu-
sive (at 5 years). Patients could either have a 
Locoregional Recurrence or a Distant (Meta-
static) Recurrence.
●  Death could occur after the No Recurrence, the 
Locoregional Recurrence, or the Distant (Meta-
static) Recurrence states
●  In the base-case analysis, we assumed that the costs 
of fourth- and fifth-line chemotherapy regimens 
were identical to those of third-line chemotherapy.
●  In the base-case analysis, we assumed that fil-
grastim (g-c s f ) was given secondary to an episode 
of febrile neutropenia, per the t a c –f a c  study.
●  A weight of 60 kg and 7 days of g-c s f  therapy per 
cycle were assumed for patients receiving g-c s f .
●  Only grade 3 or 4 adverse events with statistic-
ally significant differences were considered in 
the analysis. These included febrile neutropenia, 
infection, stomatitis, and diarrhea (Table v).
●  For patients experiencing anemia, only needed 
blood transfusions were costed and included in 
the analysis.
At baseline, the median age of patients in the t a c –f a c  
study was 49 years. The duration of the study was 
5 years. Life expectancy was extrapolated based on 
the Wisconsin population for a woman starting at 
55 years of age 18, corresponding approximately to 
the mean age of the women completing the clinical 
trial. A life expectancy was assigned to each patient 
according to health status at the end of the t a c –f a c  
clinical trial time horizon. It should also be noted 
that the adverse event rates used in the primary 
g-c s f prophylaxis sensitivity analysis were taken 
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from the g e i c a m  study, because those rates provided 
information about adverse events after primary pro-
phylaxis (Table v).
4.  RESULTS
The base-case analysis used in this model applied a 
5% discount rate, the Canadian costs for chemothera-
pies recommended by c c o  guidelines 10, and febrile 
neutropenia rates based on the available t a c –f a c  
study results 17. The incremental cost-effectiveness 
ratio (i c e r ) for t a c  compared with f a c  was $6,921.24/
l y  gained. The incremental cost–utility ratio (i c u r ) 
for t a c  compared with f a c  was $6,848.39/q a l y 
(Table iv).
Several one-way and probabilistic sensitivity 
analyses were conducted. Adverse event rates used 
in the base-case model were altered in a variety of 
ways in the sensitivity analyses. When the rates 
were increased by 25%, the incremental ratios were 
$7,129.14/l y  gained and $7,054.09/q a l y  gained. 
When decreased by 25%, the incremental ratios were 
$6,713.35/l y  gained and $6,642.68/q a l y  gained. 
When adverse event rates were increased and de-
creased by 25% in the t a c  group only, the i c e r s were 
$7,188.70/l y  gained and $6,653.78/l y  gained for t a c  
and f a c  respectively, and the i c u r s were $7,113.03/
q a l y  and $6,583.74/q a l y  respectively. Febrile neutro-
penia rates were increased and decreased by 25%, giv-
ing incremental ratios of $7,076.75/l y  and $7,002.26/
q a l y  gained and $6,765.73/l y  and $6,694.52/q a l y  
gained for t a c  and f a c  respectively.
The bootstrapping sensitivity analysis examined 
a lower and an upper bound for the cost per d f s . The 
i c e r s ranged from $3,132.16/d f s  for the best-case 
scenario to $20,370.59/d f s  for the worst-case sce-
nario. The i c u r s ranged from $3,060.59/q a l y  for the 
best-case scenario to $20,036.64/q a l y  for the worst-
case scenario.
When the model was run using the adverse events 
observed in the g e i c a m  study, in which no primary g-
c s f  prophylaxis was allowed, the i c e r  was $6,893.22/
l y  gained and the i c u r  was $6,820.66/q a l y  gained for 
t a c  compared with f a c . The results of this analysis 
were very comparable to those based on the t a c –f a c  
study, which supports our rationale for using the 
adverse events rates in the g e i c a m  study to evaluate 
the effect of primary g-c s f  prophylaxis on the cost-
effectiveness of the t a c  regimen. When g-c s f  was 
given as primary prophylaxis, the incremental costs 
were $13,183.26/l y  and $13,044.49/q a l y  gained 
for t a c  compared with f a c . The overall cost and the 
incremental benefit were both higher as compared 
with the base-case results when g-c s f  was given 
prophylactically before each cycle.
Table iv also outlines additional sensitivity 
analyses (including relapse rate, follow-up costs, 
ratio of recurrence, and utility) and additional analy-
ses with g-c s f  as a primary prophylaxis. Increases in 
the costs associated with follow-up of patients with 
No Recurrence are observed to result in increased 
i c e r s, whereas increases in the costs associated with 
follow-up of patients with Distance (Metastatic) Re-
currence are observed to result in a decreased i c e r , 
but to a far lesser extent than the increase seen with 
No Recurrence.
5.  DISCUSSION
Based on the literature, t a c  offers improved d f s  com-
pared with f a c , at a higher cost 3. Patients receiving 
t a c  had a 6-month greater life expectancy than did 
patients receiving f a c . The incremental cost-effec-
tiveness ratios for t a c  compared with f a c  ($6,921.24/
l y  gained and $6,848.39/q a l y  gained) indicate good 
economic value for t a c  treatment in the adjuvant 
setting of node-positive breast cancer patients. Life 
expectancies adjusted by utilities were lower than 
t a b l e  v  Percentage of grades 3 and 4 adverse eventsa
Adverse events t a C b [% (n evaluable pts)] f a C c
Pre Post [% (n evaluable pts)]
Febrile neutropenia
   (per protocol, in 1 or more cycles)d
24.6 (114) 6.50 (519) 2.30 (519)
Mucositis and stomatitis 20,e 6.40 (109) 2.60 (111) 2.70 (111)
Diarrhea 19,f 7.00 (114) 2.60 (519) 0.80 (519)
Infections 19,f 2.80 (109) 1.70 (111) 1.80 (111)
a  From Martin et al., 2006, Table 3 17.
b  Rates without (Pre) and with (Post) primary granulocyte colony–stimulating factor prophylaxis.
c  Rates with granulocyte colony–stimulating factor given as secondary prophylaxis.
d  Protocol definition implies a fever of 38.1°C or higher, with grade 4 neutropenia requiring intravenous antibiotics or hospitalization (or 
both), in the same cycle.
e  Based on 448 randomized subjects in total (p. 65, Table 14 17).
f  Grades 3 and 4 toxicity, with more final results. Only grades 2–4 diarrhea were reported earlier.
t a c  = docetaxel, doxorubicin, cyclophosphamide; pts = patients; f a c  = 5-fluorouracil, doxorubicin, cyclophosphamide.
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the unadjusted life expectancies, but the difference 
in q a l y s gained between the two study groups was 
greater than the observed difference in l y s gained, 
explaining why the cost per q a l y  gained is lower 
than the cost per l y  gained. According to this model, 
and based on its assumptions, t a c  is a cost-effective 
treatment for adjuvant treatment of breast cancer. 
Results show that adjuvant t a c —with secondary and 
primary prophylaxis—provides good economic value 
for women with node-positive breast cancer.
The major cost drivers of this model are the drug 
acquisition costs of t a c  and the proportion of patients 
who achieved d f s . In general, the sensitivity analy-
ses indicated that the results were robust to change. 
Variations in chemotherapy costs, follow-up costs, 
supportive care costs, and utility values resulted in 
relatively similar incremental ratios for the cost per 
l y  gained and the cost per q a l y  gained. Variations in 
rates of d f s  had a significant effect on the incremental 
ratios—namely, poor d f s  would result in a higher 
incremental ratio.
Our results were consistent with those from Au 
et al. 21, who reported a cost per q a l y  of $18,505.54. 
They used Alberta provincial costs and also based 
their analyses on the t a c –f a c  study. A similar study in 
the United Kingdom, with the same clinical trial data, 
also found that t a c  was more cost effective than f a c . 
A model was also constructed around the data from 
the b c i r g  001 trial to estimate the cost-effectiveness 
of t a c  compared with f a c  as adjuvant therapy for 
node-positive breast cancer. Parameters and sensitiv-
ity analyses were built around adverse events, cost 
of chemotherapy and support, survival estimates, 
utility weights, and costs of monitoring and care af-
ter relapse. The cost-effectiveness of t a c  compared 
with f a c  was ₤15,418/l y  gained and ₤18,188/q a l y  
gained. That study also looked at g-c s f  as primary 
prophylaxis and found an increase to ₤29,432/q a l y  
gained. Although the i c e r  was reported to be higher, 
the overall conclusions were similar to our own. The 
higher values may have resulted from the inclusion 
of additional adverse events such as anemia, pain, 
and vomiting. And because the analysis reflected 
the perspective of the U.K. National Health Service, 
differences in the cost of follow-up and community 
care may also have affected the i c e r  22.
Our study has a number of limitations. As used 
in the model, the clinical data from the t a c –f a c  trial 
and the assumptions used when trial data were not 
available to estimate long-term costs may not be 
representative of real-life experience. Hormonal 
therapies were not included in the calculation of the 
cost-effectiveness because, per the t a c -f a c  study, 
tamoxifen was administered on completion of che-
motherapy to patients with estrogen or progesterone 
receptor–positive (or both) tumours. This treatment 
strategy would have been applied to both groups, 
and thus would have not affected the results for one 
therapy or the other.
The relative cost-effectiveness of f e c-d (5-fluo-
rouracil, epirubicin, cyclophosphamide, followed by 
docetaxel), a more commonly used regimen relative 
to t a c , can be inferred from the results presented here 
and the 2008 cost-effectiveness analysis by Younis et 
al. 23, who compared the cost-effectiveness of f e c-100 
(5-fluorouracil, epirubicin, cyclophosphamide) with 
that of f e c-d in women with node-positive breast can-
cer on adjuvant chemotherapy after surgical treatment. 
Their study reported an incremental cost difference 
of $3,544 per patient and an i c u r  of $14,612/q a l y  
gained 23. They used a Markov model and reported 
the incremental cost utility over a 10-year horizon. 
Considering that the t a c  regimen has shown efficacy 
comparable to that of the f e c-100 regimen, per the 
5-year d f s s and o s s observed in the b c i r g  001 and 
p a c s  01 studies, and that the t a c  regimen is, in general, 
more costly than the f e c-100 regimen, the f e c-d regi-
men could be expected to show a cost-effectiveness 
ratio comparable to the one reported by Younis et al. or 
even better when compared with the t a c  regimen.
6.  CONCLUSIONS
Clinical results have shown that t a c  is superior to 
f a c  in terms of the primary efficacy endpoint of d f s  
and the secondary endpoint of o s . The t a c  regimen 
offered improved response at a higher cost than 
that for f a c . The incremental cost was $6,921.24/l y  
gained and $6,848.39/q a l y  gained for t a c  as com-
pared with f a c  when secondary g-c s f  prophylaxis is 
given. These costs increase to $13,183.26/l y  gained 
and $13,044.49/q a l y  gained when primary g-c s f 
prophylaxis is given in the t a c  group. Overall, the 
cost-effectiveness ratios for t a c  compared with f a c  
are low, indicating good economic value for the t a c  
treatment in the adjuvant setting of node-positive 
breast cancer patients.
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